Voyager Therapeutics (VYGR) News
NASDAQ: VYGRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.53-0.08 (-4.97%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VYGR news summary
We found 6 recent headlines mentioning Voyager Therapeutics (VYGR): 1 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, VYGR is down 4.97% at $1.53. The most recent story, "Voyager Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Pipeline Updates", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Voyager Therapeutics headlines
- Voyager Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Pipeline UpdatesVoyager Therapeutics, Inc. reported its third quarter 2026 financial results and provided updates on its clinical pipeline. The company ended the quarter on September 30, 2026, with cash, cash…Nasdaq
- Voyager Therapeutics Reports Third Quarter 2026 Financial Results and $132 Million Cash PositionVoyager Therapeutics, Inc. reported its financial and operating results for the third quarter ended September 30, 2026. The company ended the quarter with cash, cash equivalents, and marketable…Nasdaq
- Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of +2.44% and -11.00%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the…NasdaqVYGR, ROIV
- Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced…GlobeNewswire
- Voyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock Down(RTTNews) - Voyager Therapeutics Inc. (VYGR), a biotechnology company developing treatments for neurological diseases, said Wednesday Robin Swartz has been appointed president. Her appointment took…NasdaqVYGR, HEI.A
- Voyager Announces CEO Succession Plan, Appoints Robin Swartz President- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 -GlobeNewswire